29771-66-2

Upstream product

• 637-07-0 Clofibrate 

Downstream Products

• 78613-26-0 5-[1-(4-Chloro-phenoxy)-1-methyl-ethyl]-[1,3,4]oxadiazol-2-ylamine 
• 120513-10-2 C₁₆H₁₆Cl₂N₂O₄S 
• 120513-07-7 C₁₆H₁₇ClN₂O₄S 
• 120513-08-8 C₁₇H₁₉ClN₂O₄S 
• 120513-11-3 C₁₈H₂₀ClN₃O₅S 
• 120513-14-6 C₁₆H₁₆Cl₂N₂O₃S 
• 120513-15-7 C₁₇H₁₈Cl₂N₂O₃S 
• 116862-21-6 2-[1-(4-Chloro-phenoxy)-1-methyl-ethyl]-5-oxo-5H-[1,3,4]oxadiazolo[3,2-a]pyrimidine-6-carboxylic acid ethyl ester 
• 116862-16-9 2-({5-[1-(4-Chloro-phenoxy)-1-methyl-ethyl]-[1,3,4]oxadiazol-2-ylamino}-methylene)-malonic acid diethyl ester 
• 1203956-46-0 3-[1-(4-chlorophenoxy)-1-methylethyl]-4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazole 

Relevant academic research and scientific papers

Aggrecanase-2 inhibitors based on the acylthiosemicarbazide zinc-binding group

Osteoarthritis is a disabling disease characterized by the articular cartilage breakdown. Aggrecanases are potential therapeutic targets for the treatment of this pathology. At the starting point of this project, an acylthiosemicarbazide was discovered to inhibit aggrecanase-2. The acylthiosemicarbazide Zn binding group is also a convenient linker for library synthesis. A focused library of 920 analogs was thus prepared and screened to establish structure-activity relationships. The modification of the acylthiosemicarbazide was also explored. This strategy combining library design and discrete compounds synthesis yielded inhibitor 35, that is highly selective for aggrecanases over a panel of metalloproteases and inhibits the degradation of native fully glycosylated aggrecan. A docking study generated binding conformations explaining the structure-activity relationships.

TRIAZOLE DERIVATIVE OR SALT THEREOF

[Problem] A compound, which can be used for preventing or treating diseases, in which 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is concerned, in particular, diabetes, insulin resistance, dementia, schizophrenia and depression, is provided. [Means